Paxil Generalized Anxiety Relapse Prevention Data To Be Presented At APA

GlaxoSmithKline will present results from a 32-week study of Paxil in relapse prevention of generalized anxiety disorder at the American Psychiatric Association annual meeting in New Orleans May 5-10.